Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining 18F-FES with ER, 18F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method 18F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging 18F-FDG PET/CT in breast cancer.
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
Ding, Z., Xu, X., Li, T., et al. (2021) ZR-75-1 Breast Cancer Models to Study the Utility of 18F-FES by PET Imaging. Translational Cancer Research, 10, 1430-1438. https://doi.org/10.21037/tcr-20-3228
[3]
Iqbal, R., Yaqub, M., Bektas, H.O., et al. (2023) [18F]18F-FDG and [18F]18F-FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant. Clinical Cancer Research, 29, 2075-2084. https://doi.org/10.1158/1078-0432.CCR-22-2720
[4]
Breast Cancer Pro18F-FESsional Committee of China Anti-Cancer Association (2021) Guidelines and Norms for Diagnosis and Treatment of Breast Cancer of China Anti-Cancer Association (2021 Edition). Chinese Journal of Cancer, 31, 954-1040.
[5]
Du, Y.R. (2021) Research Progress of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. Chinese Journal of Endocrine Surgery, 15, 202-204.
[6]
Nienhuis, H.H., van Kruchten, M., Elias, S.G., et al. (2018) (18)F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. Journal of Nuclear Medicine, 59, 1212-1218. https://doi.org/10.2967/jnumed.117.198846
[7]
Kurland, B.F., Wiggins, J.R., Coche, A., et al. (2020) Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16alpha-18F-Fluoro-17beta-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Oncologist, 25, 835-844. https://doi.org/10.1634/theoncologist.2019-0967
[8]
Grabher, B.J. (2020) Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes. Journal of Nuclear Medicine Technology, 48, 191-201. https://doi.org/10.2967/jnmt.119.239020
[9]
Mankoff, D.A., Peterson, L.M., Tewson, T.J., et al. (2001) [18F]fltuoroestradiol Radiation Dosimetry in Human PET Studies. Journal of Nuclear Medicine, 42, 679-684.
[10]
Mathias, C.J., Welch, M.J., Katzenellenbogen, J.A., et al. (1987) Characterization of the Uptake of 16 alpha-([18F]fluoro)-17 beta-Estradiol in DMBA-Induced Mammary Tumors. International Journal of Radiation Applications and Instrumentation. Part B, 14, 15-25. https://doi.org/10.1016/0883-2897(87)90156-5
[11]
Wang, M., Glick-Wilson, B.E. and Zheng, Q.H. (2020) Fully Automated Radiosynthesis and Quality Control of Estrogen Receptor Targeting Radiopharmaceutical 16alpha-[(18)F]fluoroestradiol ([(18)F]18F-FES) for Human Breast Cancer Imaging. Applied Radiation and Isotopes, 160, Article ID: 109109. https://doi.org/10.1016/j.apradiso.2020.109109
[12]
Grabher, B. (2020) Addendum to Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Patient Outcomes. Journal of Nuclear Medicine Technology, 48, 191-201. https://doi.org/10.2967/jnmt.120.261889
[13]
Chae, S.Y., Ahn, S.H., Kim, S.-B., et al. (2019) Diagnostic Accuracy and Safety of 16α-[18F]fluoro-17β-Oestradiol PET-CT for the Assessment of Oestrogen Receptor Status in Recurrent or Metastatic Lesions in Patients with Breast Cancer: A Prospective Cohort Study. The Lancet Oncology, 20, 546-555. https://doi.org/10.1016/S1470-2045(18)30936-7
[14]
Mo, J.A. (2021) Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: A Systematic Review and Meta-Analysis. Journal of Korean Medical Science, 36, e271. https://doi.org/10.3346/jkms.2021.36.e271
[15]
Zhu, X., Wang, Y.M., Song, X.Y., et al. (2016) Analysis of the Value of F-18F-FES PET/CT Examination in Diagnosis of Breast Cancer and Evaluation of Curative Effect. Shandong Medicine, 56, 19-22.
[16]
Lee, Y., Yoo, I.R. and Ha, S. (2022) 18F-FES PET/CT for Characterization of Brain and Leptomeningeal Metastasis in Double Primary Cancer Patient. Clinical Nuclear Medicine, 47, e554-e556. https://doi.org/10.1097/RLU.0000000000004197
[17]
Kiatkittikul, P., Promteangtrong, C., Kunawudhi, A., et al. (2022) Discrepancy between [18F]-18F-FES and [18F]-18F-FDG PET/CT in ER-Positive Breast Cancer with Oesophageal Metastasis. European Journal of Nuclear Medicine and Molecular Imaging, 49, 3297-3298. https://doi.org/10.1007/s00259-022-05759-z
[18]
Yang, Z., Xie, Y., Liu, C., et al. (2021) The Clinical Value of (18)F-Fluoroestradiol in Assisting Individualized Treatment Decision in Dual Primary Malignancies. Quantitative Imaging in Medicine and Surgery, 11, 3956-3965. https://doi.org/10.21037/qims-20-1364
[19]
Yamada, S., Tsuyoshi, H., Yamamoto, M., et al. (2021) Prognostic Value of 16alpha-(18)F-Fluoro-17beta-Estradiol PET as a Predictor of Disease Outcome in Endometrial Cancer: A Prospective Study. Journal of Nuclear Medicine, 62, 636-642. https://doi.org/10.2967/jnumed.120.244319
[20]
Roze, J.F., van Meurs, H.S., Monroe, G.R., et al. (2021) [(18)F]18F-FDG and [(18)F]18F-FES Positron Emission Tomography for Disease Monitoring and Assessment of Anti-Hormonal Treatment Eligibility in Granulosa Cell Tumors of the Ovary. Oncotarget, 12, 665-673. https://doi.org/10.18632/oncotarget.27925
[21]
Peterson, L.M., Kurland, B.F., Yan, F., et al. (2021) (18)F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2-Metastatic Breast Cancer. Journal of Nuclear Medicine, 62, 184-190. https://doi.org/10.2967/jnumed.120.244459
[22]
He, S., Wang, M., Zhang, Y., et al. (2019) Monitoring the Early Response of Fulvestrant plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal (18)F-18F-FES PET/CT. Contrast Media Mol Imaging, 2019, Article ID: 2374565. https://doi.org/10.1155/2019/2374565
[23]
Liu, S., Gu, B., Zhang, J., et al. (2018) The Feasibility of (18)F-18F-FES and (18)F-18F-FDG microPET/CT for Early Monitoring the Effect of Fulvestrant on Sensitizing Docetaxel by Downregulating ERalpha in ERalpha+ Breast Cancer. Annals of Nuclear Medicine, 32, 272-280. https://doi.org/10.1007/s12149-018-1245-0
[24]
He, M., Liu, C., Shi, Q., et al. (2020) The Predictive Value of Early Changes in (18)F-Fluoroestradiol Positron Emission Tomography/Computed Tomography during Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist, 25, 927-936. https://doi.org/10.1634/theoncologist.2019-0561
[25]
Yang, Z., Sun, Y., Xue, J., et al. (2013) Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer?—A Pilot Study. PLOS ONE, 8, e78192. https://doi.org/10.1371/journal.pone.0078192
[26]
Chae, S.Y., Kim, S.B., Ahn, S.H., et al. (2017) A Randomized Feasibility Study of (18)F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer. Journal of Nuclear Medicine, 58, 563-568. https://doi.org/10.2967/jnumed.116.178368
[27]
Kumar, M., Salem, K., Michel, C., et al. (2019) (18)F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-alpha Mutations in Breast Cancer. Journal of Nuclear Medicine, 60, 1247-1252. https://doi.org/10.2967/jnumed.118.224667
[28]
Kumar, M., Salem, K., Jeffery, J.J., et al. (2021) Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating ESR1 Mutation. Journal of Nuclear Medicine, 62, 500-506. https://doi.org/10.2967/jnumed.120.249508
[29]
Boers, J., Venema, C.M., de Vries, E.F.J., et al. (2020) Molecular Imaging to Identify Patients with Metastatic Breast Cancer Who Benefit from Endocrine Treatment Combined with Cyclin-Dependent Kinase Inhibition. European Journal of Cancer, 126, 11-20. https://doi.org/10.1016/j.ejca.2019.10.024
[30]
Besret, L., d’Heilly, S., Aubert, C., et al. (2020) Translational Strategy Using Multiple Nuclear Imaging Biomarkers to Evaluate Target Engagement and Early Therapeutic Efficacy of SAR439859, a Novel Selective Estrogen Receptor Degrader. EJNMMI Research, 10, Article No. 70. https://doi.org/10.1186/s13550-020-00646-w
[31]
Liu, C., Hu, S., Xu, X., et al. (2022) Evaluation of Tumour Heterogeneity by (18)F-Fluoroestradiol PET as a Predictive Measure in Breast Cancer Patients Receiving Palbociclib Combined with Endocrine Treatment. Breast Cancer Research, 24, Article No. 57. https://doi.org/10.1186/s13058-022-01555-7
[32]
Xie, Y., Du, X., Zhao, Y., et al. (2022) Chemotherapy Shows a Better Efficacy than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-18F-FES PET. Cancers (Basel), 14, Article No. 3531. https://doi.org/10.3390/cancers14143531
[33]
Bottoni, G., Piccardo, A., Fiz, F., et al. (2021) Heterogeneity of Bone Metastases as an Important Prognostic Factor in Patients Affected by Oestrogen Receptor-Positive Breast Cancer. The Role of Combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. European Journal of Radiology, 141, Article ID: 109821. https://doi.org/10.1016/j.ejrad.2021.109821
[34]
Tsujikawa, T., Makino, A., Mori, T., et al. (2022) PET Imaging of Estrogen Receptors for Gynecological Tumors. Clinical Nuclear Medicine, 47, 481-488. https://doi.org/10.1097/RLU.0000000000004258
[35]
Liu, C., Gong, C., Liu, S., et al. (2019) (18)F-18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with (18)F-18F-FDG PET/CT. Oncologist, 24, e1277-e1285. https://doi.org/10.1634/theoncologist.2019-0096
[36]
Sadaghiani, M.S., Rowe, S.P. and Sheikhbahaei, S. (2021) Applications of Artificial Intelligence in Oncologic (18)F-18F-FDG PET/CT Imaging: A Systematic Review. Annals of Translational Medicine, 9, 823. https://doi.org/10.21037/atm-20-6162
[37]
Chae, S.Y., Son, H.J., Lee, D.Y., et al. (2020) Comparison of Diagnostic Sensitivity of [(18)F]fluoroestradiol and [(18)F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Breast Cancer Recurrence in Patients with a History of Estrogen Receptor-Positive Primary Breast Cancer. EJNMMI Research, 10, Article No. 54. https://doi.org/10.1186/s13550-020-00643-z
[38]
Ulaner, G.A., Jhaveri, K., Chandarlapaty, S., et al. (2021) Head-to-Head Evaluation of (18)F-18F-FES and (18)F-18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. Journal of Nuclear Medicine, 62, 326-331. https://doi.org/10.2967/jnumed.120.247882
[39]
Ryu, J., Jeong, J.H., Moon, D.H., et al. (2022) Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [(18)F]-18F-FES PET/CT: A Case Report. Nuclear Medicine and Molecular Imaging, 56, 105-109. https://doi.org/10.1007/s13139-022-00736-8
[40]
Bodapati, S., Abraham, P., Chen, A., et al. (2022) 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature. Tomography, 8, 1060-1065. https://doi.org/10.3390/tomography8020086
[41]
Boers, J., Schroder, C.P., Hospers, G.A.P., et al. (2021) Detection of Dural Metastases before the Onset of Clinical Symptoms by 16alpha-[18F]Fluoro-17beta-Estradiol PET in a Patient with Estrogen Receptor-Positive Breast Cancer. Clinical Nuclear Medicine, 46, e165-e167. https://doi.org/10.1097/RLU.0000000000003382
[42]
Kurland, B.F., Peterson, L.M., Lee, J.H., et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clinical Cancer Research, 23, 407-415. https://doi.org/10.1158/1078-0432.CCR-16-0362
[43]
Chudgar, A.V. and Mankoff, D.A. (2017) Molecular Imaging and Precision Medicine in Breast Cancer. PET Clinics, 12, 39-51. https://doi.org/10.1016/j.cpet.2016.08.001
[44]
Takahashi, M., Maeda, H., Tsujikawa, T., et al. (2021) 18F-Fluoroestradiol Tumor Uptake Is Influenced by Structural Components in Breast Cancer. Clinical Nuclear Medicine, 46, 884-889. https://doi.org/10.1097/RLU.0000000000003835
[45]
Linden, H.M., Peterson, L.M. and Fowler, A.M. (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clinics, 13, 415-422. https://doi.org/10.1016/j.cpet.2018.02.005
